Therapeutic options for early cancer of the esophagogastric junction

Félix Junquera, Sonia Fernández-Ananín, Carmen Balagué

Research output: Contribution to journalArticleResearch

1 Citation (Scopus)


© 2019 AEC Early-stage (T1) esophagogastric junction cancer continues to represent 2-3% of all cases. Adenocarcinoma is the most frequent and important type, the main risk factors for which are gastroesophageal reflux and Barrett's esophagus with dysplasia. Patients with mucosal (T1a) or submucosal (T1b) involvement initially require a thorough digestive endoscopy, and narrow-band imaging can improve visualization. Endoscopic treatment of these lesions includes endoscopic mucosal resection, radiofrequency ablation and endoscopic submucosal dissection. Accurate staging is necessary in order to provide optimal treatment. The most precise staging technique in these cases is endoscopic ultrasound. The suspicion of deep invasion of the submucosa, presence of unfavorable anatomopathological characteristics or impossibility to perform endoscopic resection make it necessary to consider surgical resection.
Original languageEnglish
Pages (from-to)438-444
JournalCirugia Espanola
Publication statusPublished - 1 Oct 2019


  • Adenocarcinoma
  • Barrett's esophagus
  • Early cancer
  • Endoscopic mucosal resection
  • Endoscopic submucosal dissection
  • Esophagogastric junction
  • Radiofrequency ablation


Dive into the research topics of 'Therapeutic options for early cancer of the esophagogastric junction'. Together they form a unique fingerprint.

Cite this